Peter C. Hollenhorst, PhD

Bio

Dr. Peter Hollenhorst received a B.S. from St. Norbert College and a Ph.D. in Biomolecular Chemistry from the University of Wisconsin-Madison. His doctoral research, mentored by Dr. Catherine Fox, focused on transcription factor function in yeast. Dr. Hollenhorst was an American Cancer Society postdoctoral fellow at the Huntsman Cancer Institute, University of Utah. His postdoctoral work in Dr. Barbara Graves' lab focused on deciphering genomic targets of ETS family transcription factors. Dr. Hollenhorst joined IUSM-Bloomington in 2010 and was promoted to Professor in 2022. Dr. Hollenhorst's group focuses on specificity in transcription factor families, and roles of transcription factors in cancer.

Hollenhorst Lab Website:
http://hollenhorstlab-iu.strikingly.com/

Key Publications

Nicholas, T.R., Metcalf, S.A., Greulich, B.M., and P.C. Hollenhorst. (2021) Androgen signaling connects short isoform production to breakpoint formation at Ewing sarcoma breakpoint region 1. NAR Cancer 3(3):zcab033.

Strittmatter, B.G., Jerde, T.J., and P.C. Hollenhorst. (2021) Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells. PLoS Genetics https://doi.org/10.1371/journal.pgen.1009708.

Greulich, B.M., Plotnik, J.P., Jerde, T.J., and P.C. Hollenhorst (2021). Toll-like receptor 4 signaling activates ERG function in prostate cancer and provides a therapeutic target. NAR Cancer 3(1): zcaa046.

Nicholas, T.R., Meng, J., Greulich, B.M., Morris, T.S., and P.C. Hollenhorst (2020). A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS. PLoS One 15(9): e0238999.

Budka, J.A., Ferris, M.W., Capone, M.J., and P.C. Hollenhorst. (2018). Common ELF1 deletion in prostate cancer bolsters oncogenic ETS function, inhibits senescence and promotes docetaxel resistance. Genes and Cancer 9(5-6):198-214.

Madison, B.J., Clark, K.A., Bhachech, N., Hollenhorst, P., Graves, B.J., and S.L. Currie. (2018) Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites. Journal of Biological Chemistry 293(48):18624-18635.

Damayanti, N.P., Budka, J.A., Khella, H.W.Z., Ferris, M.W., Ku, S.Y., Kauffman, E., Wood, A.C., Ahmed, K., Chintala, V.N., Adelaiye-Ogala, R., Elbanna, M., Orillion, A., Chintala, S., Kao, C., Linehan, W.M., Yousef, G.M., Hollenhorst, P.C., and R. Pili. (2018). Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma. Clinical Cancer Research 24(23):5977-5989.

Tomar, S., Plotnik, J.P., Haley, J., Scantland, J., Dasari, S., Sheikh, Z., Emerson, R., Lenz, D., Hollenhorst, P.C., and A.K. Mitra. (2017). ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase. Cancer Letters 414:190-204.

Adelaiye-Ogala, R., Budka, J., Damayanti, N.P., Arrington, J., Ferris, M.W., Hsu, C.C., Chintala, S., Orillion, A.R., Miles, K.M., Shen, L., Elbanna, M., Ciamporcero, E., Arisa, S., Pettazzoni, P., Draetta, G.F., Seshadri, M., Hancock, B.A., Radovich, M., Kota, J., Buck, M., Keilhack, H., McCarthy, B.P., Persohn, S.A., Territo, P.R., Zang, Y., Irudayaraj, J., Tao, A.W., Hollenhorst, P., and R. Pili. (2017). EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Research 77(23):6651-6666.

Kedage, V., Strittmatter, B.G., Dausinas, P.B., and P.C. Hollenhorst. (2017). Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2 allowing target gene activation. Journal of Biological Chemistry 292(42): 17225-17235.